Labcorp Expects 2024 Adjusted EPS Of $14.30-$14.70 Versus Prior Guidance Of $14.30-$14.90 And Consensus Of $14.56
|
|
| Previous |
| Updated |
| Results |
| 2024 Guidance |
| 2024 Guidance |
|
|
|
|
|
|
|
|
| 2023 |
| Low | High |
| Low | High |
| Revenue |
|
|
|
|
|
|
|
| Labcorp Enterprise (1)(2) | $12.2 |
| 6.4 % | 7.5 % |
| 6.6 % | 7.3 % |
| Diagnostics Laboratories | $9.4 |
| 6.9 % | 7.9 % |
| 7.2 % | 7.8 % |
| Biopharma Laboratory Services (3) | $2.8 |
| 3.7 % | 5.0 % |
| 4.7 % | 5.6 % |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Adjusted EPS | $13.56 |
| $14.30 | $14.90 |
| $14.30 | $14.70 |
|
|
|
|
|
|
|
|
| Free Cash Flow from Cont. Ops(4) | $0.89 |
| $0.85 | $1.00 |
| $0.85 | $0.98 |
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。